A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC
Clinical trial NCT04982549 · UNKNOWN
Trial details
- NCT number
- NCT04982549
- Sponsor
- Shandong Cancer Hospital and Institute
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-01-21
- Primary completion
- 2022-12-01
- Enrollment
- 35
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.